DURHAM, N.C., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq: HTBX ), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Jeff Wolf, Heat’s Chief Executive Officer, will deliver a corporate presentation at the 8 th Annual Biotech Showcase™, being held January 11-13, 2016 in San Francisco, CA.
8 th Annual Biotech Showcase™ Date: Wednesday, January 13, 2016 Time: 11:30 a.m. Pacific Time Location: Parc 55 San Francisco Union Square Hotel – Room: Mission II (4 th Floor)
Links to a live audio webcast and replay of the presentation may be accessed on Heat Biologics’ website at http://ir.heatbio.com/events-presentations .
About Heat Biologics, Inc. Heat Biologics, Inc. (Nasdaq: HTBX ) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT , form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); T cell co-stimulation to further enhance patients’ immune response; and reversal of tumor-induced immune suppression. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com .
CONTACT: Heat Biologics, Inc. Jennifer Almond Investor and Media Relations 919-240-7133 investorrelations@heatbio.com
